Specifically, various drugs have been designed to target SF3B1 (a central/essential core-component of the spliceosome) [16, 35, 48], making this spliceosome element the best candidate to study its translational oncogenic implication and therapeutic capacity in cancers wherein there are no successful treatments or cure. Here, SF3B1 is linked to cancer.